An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

Trial Profile

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2016

At a glance

  • Drugs Indusatumab vedotin (Primary)
  • Indications Gastrointestinal cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Millennium
  • Most Recent Events

    • 13 May 2016 Results assessing safety, pharmacokinetics and antitumor activity of TAK-264 published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 01 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Feb 2014 Planned End Date changed from 1 Mar 2015 to 1 Oct 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top